Sensus Healthcare (SRTS) AI Stock Analysis

• Market Cap: $57.21M
• Dividend Yield: N/A
• Average Volume (3M): 74.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: 3.30%
• EPS Growth: -112.70%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.06
• Shares Outstanding: 16,440,037
• 10 Day Avg. Volume: 60,677
• 30 Day Avg. Volume: 74,391
• PEG Ratio: 0.01
• Price to Book (P/B): 2.02
• Price to Sales (P/S): 2.70
• P/FCF Ratio: -101.97
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 2.85
• Enterprise Value/Ebitda: -65.64
• 1Y Price Target: $8.00
• Price Target Upside: 129.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): $30.81M

• Rating: 61 Neutral
• Price Target: $3.50 ▲(0.57% Upside)

Sensus Healthcare's overall score reflects strong financial performance and promising strategic initiatives, such as international expansion and potential Medicare reimbursement improvements. However, technical indicators show weak momentum, and valuation metrics are concerning due to recent losses. The earnings call presents a mixed sentiment, balancing growth opportunities with current financial challenges.

Positive Factors

International Expansion

Growing international demand, especially in China, and MDSAP certification open new markets, enhancing long-term growth potential.

Proposed Medicare Fee Schedule

Increased reimbursement could boost demand in the U.S., transforming commercial strategy and enhancing revenue prospects.

Strong Balance Sheet

A strong equity position and low debt enhance financial stability, providing a solid foundation for future investments and growth.

Negative Factors

Revenue Decline

A decline in revenue due to fewer capital system sales indicates potential challenges in maintaining sales momentum and market share.

Gross Margin Decrease

Decreased gross margins suggest increased cost pressures and reduced pricing power, impacting profitability and operational efficiency.

LCD and Reimbursement Challenges

Reimbursement uncertainties from the proposed LCD could hinder sales and customer adoption, affecting future revenue streams.

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

How the Company Makes Money

Sensus Healthcare generates revenue through the sale of its medical devices, specifically the SRT-100 system and its associated accessories. The company also earns income from service contracts, maintenance agreements, and consumables related to the use of its devices. Additionally, Sensus Healthcare may benefit from strategic partnerships with healthcare providers and institutions, which can enhance its market reach and provide access to new customer segments. The company may also explore collaborations for research and development, further expanding its product offerings and potential revenue streams.

Sensus Healthcare Financial Statement Overview

Summary

Sensus Healthcare has shown strong revenue and profit growth, with a robust balance sheet characterized by low leverage and high equity. However, cash flow remains a challenge due to negative free cash flow, indicating a need for improved cash management strategies.

Income Statement

Sensus Healthcare showed remarkable revenue growth of 71.3% from the previous year. The gross profit margin improved significantly to 58.4%, reflecting increased operational efficiency. Net profit margin also improved substantially to 15.9%, indicating enhanced profitability. However, the EBIT margin of 19.3% and EBITDA margin of 19.3% suggest room for improvement in controlling operating expenses.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 89.8%, demonstrating financial stability. The debt-to-equity ratio is low at 0.01, indicating minimal leverage and reduced financial risk. Return on equity improved significantly to 11.9%, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects solid financial health.

Cash Flow

Sensus Healthcare's free cash flow improved but remains negative, indicating potential challenges in cash management. The operating cash flow to net income ratio is negative, suggesting a need to enhance cash generation from operations. Despite these challenges, the free cash flow deficit has narrowed, showing some progress towards achieving positive cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.56M	41.81M	24.41M	44.53M	27.04M	9.58M
Gross Profit	19.60M	24.43M	14.06M	29.63M	16.99M	5.25M
EBITDA	-850.00K	8.52M	79.00K	15.15M	4.73M	-6.10M
Net Income	-848.00K	6.65M	485.00K	24.24M	4.12M	-6.84M
Balance Sheet
Total Assets	58.85M	62.16M	53.71M	56.73M	32.24M	28.01M
Cash, Cash Equivalents and Short-Term Investments	22.16M	22.06M	23.15M	25.52M	14.52M	14.91M
Total Debt	595.00K	602.00K	783.00K	1.02M	225.00K	1.38M
Total Liabilities	6.79M	6.34M	4.87M	8.67M	6.22M	6.51M
Stockholders Equity	52.06M	55.83M	48.84M	48.07M	26.02M	21.50M
Cash Flow
Free Cash Flow	3.50M	-1.11M	-2.37M	-1.57M	-414.00K	-792.73K
Operating Cash Flow	3.57M	-831.00K	-2.15M	-1.41M	-286.00K	-434.18K
Investing Cash Flow	-74.00K	-276.00K	-187.00K	14.84M	129.00K	7.03M
Financing Cash Flow	-302.00K	15.00K	-40.00K	-2.43M	-231.00K	210.01K

Sensus Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.48
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 3.48 is above the 20-day moving average (MA) of 3.27, above the 50-day MA of 3.25, and below the 200-day MA of 4.49, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 59.03 is Neutral, neither overbought nor oversold. The STOCH value of 21.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.

Sensus Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	61 Neutral	$57.21M	―	-1.62%	―	3.30%	-112.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NSPR	48 Neutral	$88.66M	-2.52	-87.61%	―	7.60%	-0.78%
HYPR	47 Neutral	$96.28M	-1.97	-77.26%	―	-9.59%	8.78%
CTSO	44 Neutral	$49.66M	-4.34	-68.84%	―	-7.81%	65.39%
ICCM	40 Underperform	$49.74M	-2.63	-230.80%	―	-16.46%	4.14%
RBOT	39 Underperform	$30.45M	-0.46	-125.63%	―	―	6.48%

Sensus Healthcare Corporate Events

Sensus Healthcare Faces Mixed Earnings Amid Challenges

The recent earnings call for Sensus Healthcare, Inc. painted a mixed picture for the company. While there were notable advancements in international expansion and FDA treatment volume, these positive developments were overshadowed by declines in revenue and gross profit, as well as increased operating expenses. The proposed local coverage determination (LCD) has also introduced uncertainty, affecting domestic sales momentum.

Sensus Healthcare Reports Q2 2025 Financial Results

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for skin conditions, primarily operating in the healthcare sector with a focus on superficial radiotherapy (SRT) technology. In its second quarter of 2025, Sensus Healthcare reported revenues of $7.3 million, a decrease from the previous year’s $9.2 million. The company shipped 19 SRT systems, including international shipments, and saw a 27% increase in FDA treatment volume compared to the first quarter. Despite these operational achievements, the company faced a net loss of $1.0 million, attributed to lower sales and increased costs. Sensus Healthcare also announced strategic partnerships and certifications aimed at expanding its market presence and enhancing its product offerings. Looking ahead, the company anticipates favorable impacts from proposed changes in reimbursement policies, which could boost the adoption of its SRT technology starting in 2026.